TY  - INPR
A1  - Chiu, Winston
A1  - Verschueren, Lore
A1  - Eynde, Christel van der
A1  - Buyck, Christophe
A1  - De Meyer, Sandra
A1  - Jochmans, Dirk
A1  - Bojkova, Denisa
A1  - Ciesek, Sandra
A1  - Cinatl, Jindrich
A1  - De Jonghe, Steven
A1  - Leyssen, Pieter
A1  - Neyts, Johan
A1  - Loock, Marnix van
A1  - Damme, Ellen van
T1  - Development and optimisation of a high-throughput screening assay for in vitro antiSARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
T2  - bioRxiv
N2  - Although vaccines are currently used to control the coronavirus disease 2019 (COVID-19) pandemic, treatment options are urgently needed for those who cannot be vaccinated and for future outbreaks involving new severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) strains or coronaviruses not covered by current vaccines. Thus far, few existing antivirals are known to be effective against SARS-CoV-2 and clinically successful against COVID-19.
As part of an immediate response to the COVID-19 pandemic, a high-throughput, high content imaging–based SARS-CoV-2 infection assay was developed in VeroE6-eGFP cells and was used to screen a library of 5676 compounds that passed phase 1 clinical trials. Eight candidates (nelfinavir, RG-12915, itraconazole, chloroquine, hydroxychloroquine, sematilide, remdesivir, and doxorubicin) with in vitro anti–SARS-CoV-2 activity in VeroE6-eGFP and/or Caco-2 cell lines were identified. However, apart from remdesivir, toxicity and pharmacokinetic data did not support further clinical development of these compounds for COVID-19 treatment.
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/73013
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-730138
IS  - 2022.02.02.478671
ER  -